Becton, Dickinson and Company (BDX)
BDX Completes PREVENT Trial Enrollment for Phasix Mesh Study
BD concludes PREVENT trial enrollment, advancing Phasix Mesh toward a potential FDA submission for incisional hernia prevention.
Buy, Sell, or Hold These 4 Dividend Kings After Earnings: BDX, ED, EMR, PH
Four Dividend Kings - Becton, Dickinson and Company (BDX), Consolidated Edison (ED), Emerson Electric (EMR), and Parker-Hannifin (PH) - reported earnings last week.
Becton, Dickinson and Company Q3 Earnings Call Highlights
Becton, Dickinson and Company NYSE: BDX reported third-quarter fiscal 2026 revenue of $5 billion, up 4.4% on an FX-neutral basis, as growth across its key platforms and operational productivity helped results exceed the company's expectations.
BD Stock Up in Pre-Market Post Q3 Earnings & Revenue Beat, Margins Down
BDX tops third-quarter fiscal 2026 earnings and revenue estimates as broad segment growth offset pressure on gross and operating margins.
Becton, Dickinson and Company (BDX) Q3 2026 Earnings Call Transcript
Becton, Dickinson and Company (BDX) Q3 2026 Earnings Call Transcript
Becton Dickinson (BDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Becton Dickinson (BDX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Becton Dickinson (BDX) Q3 Earnings and Revenues Surpass Estimates
Becton Dickinson (BDX) came out with quarterly earnings of $3.23 per share, beating the Zacks Consensus Estimate of $3.14 per share. This compares to earnings of $3.68 per share a year ago.
Can Segment Strength Offset Headwinds for BD Stock Before Q3 Earnings?
BDX's Medical Essentials and Interventional strength may drive third-quarter fiscal 2026 results, but China, vaccines and projected declines weigh on expectations.
Countdown to Becton Dickinson (BDX) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Evaluate the expected performance of Becton Dickinson (BDX) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Becton, Dickinson - Stable Undervaluation In 1Q26, Upside Is There
Becton, Dickinson and Company is undervalued, trading at 12–13x P/E despite forecasted 7%–8% annual growth and improving fundamentals. BDX's sector-wide pressures are driven by cautious hospital spending, higher rates, and capital rotation into AI, but its core operations remain robust. BDX maintains a BBB rating, conservative leverage, a 2.78% dividend with 44+ years of increases, and is executing $2B in buybacks while retiring $2.1B in debt.
Here's Why You Should Retain BDX Stock in Your Portfolio Now
Becton, Dickinson's MedTech focus, innovation push and strategic partnerships support growth optimism, though reimbursement uncertainty remains a key concern.
